| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-01-26 |
复牌提示：
2021-01-25 19:50:04 停牌，复牌日期 2021-01-27 00:00:01
|
| 2021-01-26 |
详情>>
内部人交易：
BridgeBio Pharma, Inc.等共交易6笔
|
| 2020-12-15 |
股东大会：
将于2021-01-19召开股东大会
会议内容 ▼▲
- 1.A proposal to adopt the Agreement and Plan of Merger, dated as of October 5, 2020, by and among Eidos, BridgeBio Pharma, Inc. (“BridgeBio”), Globe Merger Sub I, Inc. and Globe Merger Sub II, Inc., a copy of which is attached as Annex A to the accompanying joint proxy statement/prospectus, and approve the mergers and other transactions contemplated thereby (the “Eidos merger proposal”);
2.A proposal to approve, on a non-binding, advisory basis, the compensation that will or may become payable to the named executive officers of Eidos in connection with the consummation of the mergers (the “Eidos advisory compensation proposal”);
3.A proposal to approve the adjournment of the Eidos special meeting to another date and place, if necessary or appropriate, to solicit additional votes in favor of the Eidos merger proposal (the “Eidos adjournment proposal”).
|
| 2020-12-15 |
详情>>
股本变动：
变动后总股本3886.19万股
|
| 2020-10-29 |
详情>>
业绩披露：
2020年三季报(累计)每股收益-2.14美元,归母净利润-8184.9万美元,同比去年增长-334.1%
|
| 2020-08-06 |
详情>>
业绩披露：
2020年中报每股收益-1.35美元,归母净利润-5167.3万美元,同比去年增长-100.39%
|
| 2020-05-08 |
详情>>
业绩披露：
2020年一季报每股收益-0.6美元,归母净利润-2282.4万美元,同比去年增长-94.53%
|
| 2020-04-24 |
股东大会：
将于2020-05-27召开股东大会
会议内容 ▼▲
- 1.To elect six (6) director nominees to the Board of Directors to hold office until the 2021 Annual Meeting of Stockholders or until their successors are duly elected and qualified.
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020.
3.To approve an amendment and restatement of the Company’s Amended and Restated 2018 Stock Option and Incentive Plan (the “Amended and Restated Plan”) to, among other things, increase the number of shares of common stock reserved for issuance thereunder by 1,500,000 shares.
4.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2020-02-26 |
详情>>
业绩披露：
2019年年报每股收益-1.03美元,归母净利润-3783.5万美元,同比去年增长4.97%
|
| 2020-02-26 |
详情>>
业绩披露：
2017年年报每股收益-3.32美元,归母净利润-1194.1万美元,同比去年增长-369.75%
|
| 2019-10-31 |
详情>>
业绩披露：
2019年三季报(累计)每股收益-0.52美元,归母净利润-1885.5万美元,同比去年增长48.17%
|
| 2019-08-01 |
详情>>
业绩披露：
2018年中报每股收益-3.06美元,归母净利润-1934.4万美元,同比去年增长-376.81%
|
| 2019-08-01 |
详情>>
业绩披露：
2019年中报每股收益-0.71美元,归母净利润-2578.6万美元,同比去年增长-33.3%
|
| 2019-05-07 |
详情>>
业绩披露：
2019年一季报每股收益-0.32美元,归母净利润-1173.3万美元,同比去年增长-47.34%
|
| 2019-04-29 |
股东大会：
将于2019-06-12召开股东大会
会议内容 ▼▲
- 1.To elect five (5) director nominees to the Board of Directors to hold office until the 2020 Annual Meeting of Stockholders or until their successors are duly elected and qualified.
2.To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2019.
3.To approve the Amended and Restated 2018 Stock Option and Incentive Plan (the “Amended and Restated Plan”) to, among other things, increase the number of shares of common stock reserved for issuance thereunder by 700,000 shares.
4.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2019-04-15 |
详情>>
业绩披露：
2018年年报每股收益-1.86美元,归母净利润-3981.2万美元,同比去年增长-233.41%
|
| 2018-11-06 |
详情>>
业绩披露：
2018年三季报(累计)每股收益-2.28美元,归母净利润-3637.6万美元,同比去年增长-432.59%
|